Eiger Biopharmaceuticals LLC is a United States-based commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	12.59M 10.98M 10.36M 9.41M 17.63M 1.21B 17.71M 124M 47.91M 614M 47.28M 46.23M 1.98B	P/E 2022	-0.51x	P/E 2023	-0.13x
Enterprise Value	27.95M 24.37M 23.01M 20.89M 39.15M 2.68B 39.31M 276M 106M 1.36B 105M 103M 4.39B	EV / Sales 2022	-836,796x	EV / Sales 2023	1,605,487x
Free-Float	86.47%	Yield 2022 *	-	Yield 2023	-

24-10-01	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect	CI
24-09-30	Eiger BioPharmaceuticals, Inc. Went Out of Business	CI
24-09-05	Combined Hearing for Disclosure Statement and Plan Approved for Eiger BioPharmaceuticals, Inc.	CI
24-09-05	Fifth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
24-09-04	First Motion for Exclusivity Period Extension Approved For Eiger BioPharmaceuticals, Inc.	CI
24-09-03	Fourth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
24-09-02	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
24-09-02	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
24-09-02	Eiger InnoTherapeutics, Inc. completed the acquisition of Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million.	CI
24-08-28	Third Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
24-08-21	Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	CI
24-08-15	Second Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
24-08-05	Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	CI

23-08-29	Citigroup Adjusts Eiger BioPharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	MT
23-06-30	Baird Adjusts Price Target on Eiger BioPharmaceuticals to $5 From $3, Maintains Outperform Rating	MT
22-09-07	BTIG Adjusts Eiger BioPharmaceuticals' Price Target to $48 from $57, Maintains Buy Rating	MT
21-10-11	Eiger BioPharmaceuticals : Wedbush Suspended Coverage on Eiger BioPharmaceuticals	MT
21-05-11	Eiger BioPharmaceuticals : Citigroup Adjusts Price Target on Eiger BioPharmaceuticals to $26 From $23, Maintains Buy Rating	MT

24-10-01	Eiger BioPharmaceuticals : DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE Form 8 K	PU
24-07-16	Eiger BioPharmaceuticals : THIS IS NOT A SOLICITATION OF ACCEPTANCE OR REJECTION OF THE PLAN. THE DEBTORS ARE SEEKING APPROVAL OF THE DISCLOSURE STATEMENT ON A CONDITIONAL BASIS, BUT IT HAS NOT YET BEEN APPROVED BY THE BANKRUPTCY COURT Form 8 K	PU
24-07-11	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist with FDA Breakthrough Therapy Designation	AQ
24-05-06	Sentynl Therapeutics Announces Global Acquisition of Zokinvy for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals	AQ
24-04-01	Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection	AQ

Manager	Title	Age	Since
Christopher Kurtz CTO	Chief Tech/Sci/R&D Officer	59	2022-04-17
Douglas Staut PRN	Corporate Officer/Principal	-	2024-04-18

Celladon Corp Stock Nasdaq

Stocks

US15117E1073

Biotechnology & Medical Research

Valuation: Celladon Corp

Latest news: Celladon Corp

Analysts' recommendations: Celladon Corp

Press Releases: Celladon Corp

News in other languages: Celladon Corp

Quotes and Performance

Managers and Directors: Celladon Corp

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELLADON CORP	-4.91%	-10.06%	-	-	12.59M
LONZA GROUP AG	+0.11%	+2.71%	+0.33%	+28.59%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+40.07%	+27.26%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+322.27%	+517.36%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+2.32%	+67.94%	39.9B
CELLTRION, INC.	-0.50%	+0.67%	+11.79%	+40.51%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+21.99%	+124.21%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.15%	+38.93%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-10.60%	-	14.05B
Average	-1.38%	+3.76%	+51.29%	+120.69%	29.15B
Weighted average by Cap.	-1.02%	+1.87%	+64.69%	+130.23%

	2022	2023
Net sales	13.48 11.76 11.1 10.08 18.89 1.29K 18.97 132.99 51.32 657.82 50.65 49.53 2.12K	15.77 13.75 12.99 11.79 22.1 1.51K 22.19 155.57 60.03 769.48 59.25 57.94 2.48K
Net income	-96.78M -84.39M -79.68M -72.36M -136M -9.29B -136M -954M -368M -4.72B -364M -355M -15.19B	-74.96M -65.37M -61.72M -56.05M -105M -7.19B -105M -739M -285M -3.66B -282M -275M -11.77B
Net Debt	-63.29M -55.19M -52.11M -47.32M -88.66M -6.07B -89.03M -624M -241M -3.09B -238M -232M -9.93B	15.36M 13.39M 12.65M 11.48M 21.52M 1.47B 21.61M 151M 58.46M 749M 57.7M 56.42M 2.41B